Mar 12, 2026

Incyte (INCY) has seen its stock price rise to $95.88, an increase of 11.3%, over the past six months, according to a report from Yahoo Finance. The company’s performance during this period exceeded that of the S&P 500 by 8.1 percentage points, a move attributed partly to solid quarterly results.

Company Profile and Performance Metrics

Incyte is a biopharmaceutical firm focused on developing therapeutics for cancer and inflammatory diseases. Analysis of the company’s financial history shows its sales grew at a 14% compounded annual rate over the last five years, outpacing the average for healthcare companies.

The firm’s free cash flow margin for the trailing twelve months reached…